Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

FTSE 100 rises on virus treatment hopes; AstraZeneca boosts

08/24/2020 | 04:06am EST

(For a live blog on European stocks, type LIVE/ in an Eikon news window)

* Report says U.S. mulling fast-tracking potential vaccine

* Financial, industrial stocks boost mid-cap index

* Bunzl rises on resuming dividends

* Wetherspoons slips as sales still down; calls for more VAT aid

* FTSE 100 gains 1.7%, FTSE 250 up 0.6%

Aug 24 (Reuters) - The FTSE 100 jumped on Monday after U.S. health regulators authorised a COVID-19 treatment over the weekend, while AstraZeneca boosted the index on a report the U.S. government was considering fast-tracking its experimental vaccine.

The British drugmaker gained 2.1% as the report said one option being explored would involve the U.S. health regulator awarding "emergency use authorisation" in October to the potential vaccine.

The export-laden FTSE 100 was up 1.7%, capping its best session in 12 days, while the mid-cap FTSE 250 rose 0.6%, led by financials and industrials.

"These are typical August markets where you don't have a lot that's driving them up except the absence of bad news," said Michael Hewson, a market analyst at CMC Markets UK.

The blue-chip FTSE 100 has bounced from its March lows but lagged the U.S. benchmark S&P 500, which is scaling record highs on fiscal and monetary stimulus and hopes that the worst of the pandemic's economic damage is over.

On Sunday, the U.S. Food & Drug Administration said it authorised the use of blood plasma from patients who had recovered from COVID-19 as a treatment for the disease.

"If last week was beset by the economic realities of the COVID-19 pandemic, then Monday is starting out with a (temporary) cure for those concerns," said financial analyst Connor Campbell at spreadbetters Spreadex.

The focus will turn to U.S. Federal Reserve Chair Jerome Powell's address at the Kansas City Fed's annual conference on Thursday for any hints as to the central bank's efforts to revamp its approach to monetary policy.

Bunzl Plc gained 2.8% after resuming dividends, while pub operator J D Wetherspoon fell 3% as its sales were still down sharply year-on-year despite the government's subsidised meal scheme and calls for tax relief for the hospitality sector to be extended. (Reporting by Sagarika Jaisinghani and Shreyashi Sanyal in Bengaluru; Editing by Subhranshu Sahu and Ken Ferris)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.23% 7735 Delayed Quote.1.85%
BUNZL PLC -2.21% 2300 Delayed Quote.13.51%
DJ INDUSTRIAL 0.37% 29969.31 Delayed Quote.4.67%
J D WETHERSPOON PLC -0.44% 1132.4 Delayed Quote.-31.75%
MSCI UNITED KINGDOM (STRD, UHD) -0.88% 992.939 Real-time Quote.-15.86%
NASDAQ 100 0.64% 12236.906282 Delayed Quote.39.15%
NASDAQ COMP. 0.65% 12180.465855 Delayed Quote.34.79%
S&P 500 0.31% 3641.02 Delayed Quote.12.35%
All news about ASTRAZENECA PLC
09:53aWall St rises, Nasdaq hits record high on recovery hopes
09:23aGLOBAL MARKETS LIVE: Amazon and Disney at opposite ends
09:20aWall St headed higher on recovery hopes after Thanksgiving holiday
09:15aCovid-19 Vaccine Studies May Suffer as Volunteers Consider Dropping Out
08:58aBritain and other nations press on with AstraZeneca vaccine amid trial questi..
08:48aBritain and other nations press on with AstraZeneca vaccine amid trial questi..
08:38aStocks reach records; dollar settles lower
08:22aGold faces worst week in two months as vaccine optimism weighs
07:57aASIA TODAY : South Korea cases stay above 500 for 2nd day
07:56aASIA TODAY : South Korea cases stay above 500 for 2nd day
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 46,6x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,50 $
Last Close Price 103,46 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555